Full Text of PDF (469k)
Article in Japanese
Abstract
Case Report
EGFR T790M mutation-positive lung adenocarcinoma showing progression despite serum CEA reduction after osimertinib administration: a case report
Hideto Oshitaa Kohei Kawasakib Noriaki Itoa Misato Senooa Kunihiko Funaishia Ken Okusakia
aDepartment of Internal Medicine, Mihara Medical Association Hospital
bDepartment of Internal Medicine, Mitsugi General Hospital
ABSTRACT
A 68-year-old man with adenocarcinoma was successfully treated with gefitinib. Subsequently, the tumor recurred and was epidermal growth factor receptor (EGFR) T790M mutation positive. The patient was treated with osimertinib, and his serum carcinoembryonic antigen (CEA) level significantly decreased. However, complicated deep vein thrombosis (DVT) developed, and the tumor increased in size. Despite the continuous administration of osimertinib and anticoagulation therapy, lung cancer rapidly progressed, and the patient died. The unexpected clinical course of this case could be attributed to tumor heterogeneity and histologic transformation. The disease status of cancer should not be evaluated solely on the basis of tumor markers.
KEYWORDS
Carcinoembryonic antigen (CEA) Histologic transformation Deep vein thrombosis (DVT)
Received 11 Jul 2019 ／ Accepted 13 Sep 2019
AJRS, 9(1): 61-64, 2020
Copyright © The Japanese Respiratory Society All Rights Reserved.